Nurix Therapeutics (NASDAQ:NRIX) Insider Sells $107,880.00 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 5,394 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.00, for a total transaction of $107,880.00. Following the sale, the insider directly owned 115,005 shares of the company’s stock, valued at $2,300,100. The trade was a 4.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Thursday, April 30th, Gwenn Hansen sold 3,214 shares of Nurix Therapeutics stock. The shares were sold at an average price of $16.65, for a total transaction of $53,513.10.

Nurix Therapeutics Price Performance

Shares of NRIX stock opened at $22.90 on Friday. The firm has a fifty day moving average of $16.98 and a two-hundred day moving average of $17.03. The firm has a market cap of $2.37 billion, a P/E ratio of -7.25 and a beta of 1.86. Nurix Therapeutics, Inc. has a 1-year low of $8.19 and a 1-year high of $23.72.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Wednesday, April 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). The company had revenue of $6.25 million during the quarter, compared to analyst estimates of $14.25 million. Nurix Therapeutics had a negative net margin of 411.37% and a negative return on equity of 64.21%. On average, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.88 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on NRIX. Truist Financial boosted their price target on Nurix Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, June 8th. HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of Nurix Therapeutics in a research note on Wednesday, June 10th. BTIG Research increased their target price on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, June 9th. Robert W. Baird raised their price target on shares of Nurix Therapeutics from $26.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Finally, Wells Fargo & Company lowered shares of Nurix Therapeutics from an “overweight” rating to a “hold” rating and dropped their price objective for the stock from $28.00 to $25.00 in a research note on Monday, June 8th. Fourteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.20.

Institutional Investors Weigh In On Nurix Therapeutics

A number of hedge funds have recently made changes to their positions in NRIX. Larson Financial Group LLC grew its holdings in Nurix Therapeutics by 339.0% in the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after buying an additional 1,190 shares in the last quarter. Intesa Sanpaolo Wealth Management acquired a new position in Nurix Therapeutics during the 4th quarter worth $31,000. Caitong International Asset Management Co. Ltd acquired a new position in Nurix Therapeutics during the 4th quarter worth $33,000. KBC Group NV bought a new position in shares of Nurix Therapeutics in the first quarter worth $34,000. Finally, Wexford Capital LP acquired a new position in shares of Nurix Therapeutics during the third quarter valued at $41,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.